Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

P2Y12 platelet inhibitor (antiplatelet agent)

Cangrelor

Kengrexal

Dosage form
Tablet
Available strengths
50 mg per vial
Drug class
P2Y12 platelet inhibitor (antiplatelet agent)
Common brand
Kengrexal

Clinical overview. Cangrelor, sold as Kengrexal, is a fast-acting, short-duration intravenous antiplatelet drug used during percutaneous coronary intervention to reduce the risk of heart attack, repeat revascularization, and stent thrombosis. It works by directly and reversibly blocking the P2Y12 receptor on platelets, with effects that wear off within about an hour of stopping the infusion. Cangrelor increases the risk of bleeding and is given only in a hospital setting under close monitoring.

Indication

Common therapeutic uses

  • Cangrelor is used to reduce the risk of thrombotic cardiovascular events, including periprocedural heart attack, repeat coronary revascularization, and stent thrombosis, in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).
  • Reserved for patients who have not already been treated with an oral P2Y12 platelet inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor.

Pregnancy

Risk assessment and monitoring considerations

  • No human data are available on cangrelor use during pregnancy; animal studies showed increased intrauterine deaths and delayed fetal development at higher doses.
  • Cangrelor should not be used during pregnancy unless the benefit to the mother has been carefully weighed against the potential risk to the fetus.

Breastfeeding

Infant exposure considerations

  • There are no data on whether cangrelor passes into human breast milk; because of its short half-life, exposure to a breastfed infant is expected to be very low, but the risk cannot be excluded.

Geriatrics

Dosing and tolerability considerations

  • No dose adjustment is needed in patients 75 years and older, and no overall differences in safety or effectiveness were seen compared with younger patients.

Pediatrics

Use in children and adolescents

  • No data are available to support use in patients under 18 years of age, and Health Canada has not authorized a pediatric indication.

Dosage & Administration

Practical dosing and administration

  • The recommended dose is a 30 mcg/kg intravenous bolus given rapidly (in under 1 minute), followed immediately by a 4 mcg/kg/min intravenous infusion.
  • The bolus should be started before the PCI procedure, and the infusion should generally continue for at least 2 hours or for the duration of the procedure, whichever is longer, up to a maximum of 4 hours.
  • No dosage adjustment is required for mild, moderate, or severe renal impairment, or for hepatic impairment, though the drug has not been formally studied in hepatic impairment.
  • To maintain platelet inhibition after stopping cangrelor, an oral P2Y12 inhibitor should be given immediately upon discontinuation: ticagrelor 180 mg, prasugrel 60 mg, or clopidogrel 600 mg.
  • Prasugrel and clopidogrel should not be given before cangrelor is discontinued, since this reduces their effectiveness; ticagrelor may be given during the cangrelor infusion without this concern.
  • Cangrelor is intended for use only in an acute, hospital-based setting.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • There is no specific treatment to reverse cangrelor's antiplatelet effect.
  • Platelet function returns to normal within about 1 hour after the infusion is stopped.
  • In clinical trials, overdoses of up to 10 times the intended bolus dose or 3.5 times the intended infusion dose have occurred.
  • Bleeding, generally mild to moderate, was the most frequently observed adverse event with overdose.

Common side effects

Frequently reported tolerability concerns

  • Bleeding of mild severity may occur, most commonly at the arterial puncture site.
  • Nausea may occur.
  • Vomiting may occur.
  • Vessel puncture site pain may occur.
  • Vessel puncture site swelling may occur.
  • Back pain may occur.
  • Headache may occur.
  • Hypertension may occur.
  • Hypotension may occur.
  • Dyspnea (shortness of breath) may occur, most often mild to moderate and during the infusion itself.
  • Bradycardia (slow heart rate) may occur.
  • Diarrhea may occur.
  • Dyspepsia (indigestion) may occur.
  • Fever may occur.
  • Malaise may occur.
  • Pruritus (itching) may occur.
  • Presyncope (light-headedness before fainting) may occur.
  • Urinary tract infection may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Cangrelor increases the risk of bleeding, including severe or life-threatening bleeding.
  • Intracranial hemorrhage may occur and has been fatal in some cases.
  • Cardiac tamponade may occur.
  • Serious hypersensitivity reactions, including anaphylactic reactions or shock, angioedema, bronchospasm, and stridor, may occur.
  • Worsening kidney function may occur, particularly in patients with severe renal impairment.
  • Coronary artery dissection or perforation may occur during the procedure.
  • Cardiac events, including myocardial infarction, cardiac arrest, and arrhythmias, have been reported.
  • Stroke, including hemorrhagic stroke, has been reported.
  • Seek urgent medical attention for unusual bleeding or bruising, sudden severe headache, chest pain, difficulty breathing, or signs of an allergic reaction.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with conditions associated with an increased bleeding risk, or who are taking other medications that increase bleeding risk.
  • Use with caution in patients with severe renal impairment, given the higher observed rates of bleeding and worsening kidney function in this group.
  • Use with caution in patients with a rare hereditary fructose intolerance, since the formulation contains sorbitol.
  • Monitor closely for any unexplained fall in blood pressure or hematocrit, which may indicate a hemorrhagic event requiring cangrelor discontinuation.
  • Use with caution regarding male fertility, as animal studies showed impaired fertility at high exposure levels.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with significant active bleeding or an increased risk of bleeding.
  • Contraindicated in patients with a prior ischemic stroke or any previous hemorrhagic stroke.
  • Contraindicated in patients with known hypersensitivity, including anaphylaxis, to cangrelor or any component of the product.

Drug interactions

Clinically relevant combinations

  • Clopidogrel or prasugrel given during or immediately before cangrelor infusion have reduced or abolished antiplatelet effect until cangrelor is discontinued and the next dose is given; these drugs should only be started after the cangrelor infusion ends.
  • Ticagrelor can be safely administered during the cangrelor infusion without significant loss of its antiplatelet effect.
  • Cangrelor has been co-administered with unfractionated heparin, aspirin, nitroglycerin, bivalirudin, and low molecular weight heparin without clinically significant pharmacokinetic interactions.
  • Cangrelor is not expected to interfere with the hepatic metabolism of other drugs, as neither cangrelor nor its major metabolite inhibits hepatic CYP enzymes at therapeutic concentrations.
  • Caution is advised when combining cangrelor with substrates of the BCRP transporter, based on in vitro inhibition data.

Food interactions

Meal-related administration

  • No food interactions have been established, as cangrelor is given only by intravenous infusion in a hospital setting.

Time of administration

Practical scheduling

  • Cangrelor is given as a rapid intravenous bolus followed immediately by a continuous infusion timed around the PCI procedure, under direct medical supervision.
  • The bolus must be fully administered before the PCI procedure begins.

Storage

Product handling

  • Store vials at room temperature, between 15°C and 30°C.
  • After reconstitution and dilution, the solution is stable for up to 12 hours in 5% dextrose or 24 hours in normal saline at room temperature; do not refrigerate.

Patient take-away

Key counselling points for a quick closing summary

  • Cangrelor (Kengrexal) is a fast-acting, short-duration intravenous antiplatelet drug used during coronary artery procedures, and its effects wear off within about an hour of stopping the infusion.

References

Source material and product information

  1. Health Canada Product Monograph — Cangrelor

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.